Kuros Biosciences

𝗧𝗼𝗱𝗮𝘆 𝗞𝘂𝗿𝗼𝘀 𝗕𝗶𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲𝗱 𝗶𝘁𝘀 𝟮𝟬𝟮𝟲 𝗮𝗻𝗻𝘂𝗮𝗹 𝗴𝘂𝗶𝗱𝗮𝗻𝗰𝗲 𝗮𝗻𝗱 𝗿𝗲𝗽𝗼𝗿𝘁𝗲𝗱 𝟰𝟬% 𝘆𝗲𝗮𝗿-𝗼𝘃𝗲𝗿-𝘆𝗲𝗮𝗿 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲 𝗶𝗻 𝘀𝗮𝗹𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗻𝗶𝗻𝗲 𝗺𝗼𝗻𝘁𝗵𝘀 𝗼𝗳 𝟮𝟬𝟮𝟲. 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 • Total Medical Device sales increased 40% to USD 141.8 million (9M 2025: USD 101.1 million) • Total Group EBITDA increased 81% to USD 13.5 million (9M 2025: USD 7.4 million) • The Group adjusted EBITDA* increased 68% to USD 20.6 million, equaling a margin of 14.5% (9M 2025: USD 12.2 million or 12.1%) • Cash position ahead of plan at USD 19.6 million, up from USD 9.7 million as of June 30, 2026 𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝗮𝗹 & 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 • Made in the U.S. and the Netherlands – Kuros’ new Alpharetta, Georgia facility began commercial production of MagnetOs bone graft in October 2026. Together with its Bilthoven, Netherlands site, this gives Kuros dual-site manufacturing, including production in its largest market, to support capacity and supply-chain resilience • Level I trials pass key thresholds – PROOF reached 97% enrollment and PRECISE surpassed its halfway mark at 55%, advancing both posterolateral fusion studies. ASTRA advanced to 18% in hindfoot and ankle fusion, extending prospective evidence across spine and extremities 𝗢𝘂𝘁𝗹𝗼𝗼𝗸 • Reflecting the continued strength of the business, the Group raises its full-year guidance and now expects sales growth of 36% to 40% and an adjusted EBITDA margin of more than 14.5% 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗵𝗲𝗿𝗲: https://lnkd.in/esAUuBb2 #KurosBiosciences #MagnetOs #NeedleGrip #BoneHealing #SIXSwissExchange

𝗞𝘂𝗿𝗼𝘀 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗱 𝘁𝗼𝗱𝗮𝘆 𝟰𝟱% 𝗛𝟭 𝟮𝟬𝟮𝟲 𝘆𝗲𝗮𝗿-𝗼𝘃𝗲𝗿-𝘆𝗲𝗮𝗿 𝘀𝗮𝗹𝗲𝘀 𝗴𝗿𝗼𝘄𝘁𝗵 𝗮𝗻𝗱 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲𝘀 𝗼𝘃𝗲𝗿𝗮𝗹𝗹 𝗽𝗿𝗼𝗳𝗶𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆 A dozen milestones that mark our next phase of scale – see what’s driving the momentum: 1) Total Medical Device sales +45% to USD 92.4M 2) EBITDA increased 46% to USD 7.4M 3) Adjusted EBITDA increased 61% to USD 12.5M (13.6% margin) 4) Net profit amounted to USD 4.4M 5) Cash on track; funding U.S. and Netherlands expansion 6) Ranked as the 3rd largest U.S. bone graft brand by revenue 7) Accelerating innovation and portfolio expansion 8) Strong growth in key segments across spine, extremities, trauma 9) New U.S. manufacturing site supports long-term scaling & growth operations 10) Deepening a differentiated surgeon engagement platform 11) Three Level I human clinical trials on track: PROOF, PRECISE, ASTRA 12) New evidence supports early fusion success in high-risk patients Kuros delivered strong sales growth and profitability while expanding MagnetOs adoption, advancing innovations and clinical evidence, and scaling manufacturing to support future growth. Kuros is now a profitable, high-growth medical technology company, and we enter the second half of the year with confidence, remaining firmly on track toward our long-term growth and margin targets. 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗵𝗲𝗿𝗲: https://lnkd.in/e7fWkJhc #KurosBiosciences #MagnetOs #BoneHealing #SIXSwissExchange

𝗞𝘂𝗿𝗼𝘀 𝗕𝗶𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗿𝗲𝗽𝗼𝗿𝘁𝘀 𝟱𝟭% 𝘆𝗲𝗮𝗿-𝗼𝘃𝗲𝗿-𝘆𝗲𝗮𝗿 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲 𝗶𝗻 𝘀𝗮𝗹𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝘁𝗵𝗿𝗲𝗲 𝗺𝗼𝗻𝘁𝗵𝘀 𝗼𝗳 𝟮𝟬𝟮𝟲 Chris Fair, Chief Executive Officer of Kuros Biosciences, said: "Kuros is off to a strong start in 2026, building on the momentum following a record-breaking 2025. Our commercial execution remained strong in the first quarter, and we delivered USD 43.4 million in product sales, EBITDA of USD 2.9 million and adjusted EBITDA of USD 5.7 million. At the same time, we see strong demand across spine and our growing extremities business, reflecting broader surgeon confidence in MagnetOs across indications. Our clinical story continues to strengthen, with three Level I clinical trials actively enrolling and the recently published Eskander study confirming that MagnetOs performs at early timepoints even in high-risk patient populations. Additionally, with the progress of our Atlanta facility on schedule, we are accelerating into the second quarter of 2026 with confidence.” 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹, 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝗮𝗹, 𝗮𝗻𝗱 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗵𝗲𝗿𝗲: https://lnkd.in/eiwufAGq #KurosBiosciences #MagnetOs #GrowBoneMagnetOs #NeedleGrip #Spine #Extremities #SIXSwissExchange

Today we announced our 𝟮𝟬𝟮𝟱 𝗳𝘂𝗹𝗹-𝘆𝗲𝗮𝗿 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗿𝗲𝘀𝘂𝗹𝘁𝘀, achieving 𝟳𝟮% 𝘀𝗮𝗹𝗲𝘀 𝗴𝗿𝗼𝘄𝘁𝗵 and its 𝗳𝗶𝗿𝘀𝘁-𝗲𝘃𝗲𝗿 𝗮𝗻𝗻𝘂𝗮𝗹 𝗻𝗲𝘁 𝗽𝗿𝗼𝗳𝗶𝘁. 𝟭𝟮 𝗺𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲𝘀 that mark our next phase of scale – see what’s driving the momentum: 1) Total Medical Device sales +72% to USD 146.1M 2) Direct MagnetOs™ sales +71% to USD 143.9M 3) Adjusted EBITDA reached USD 19.6M (13.4% margin) 4) First annual net profit in company history: USD 2.6M 5) Expansion into the USD 1.3B extremities market 6) First patient enrolled in ASTRA Level I global RCT 7) FDA 510(k) clearance & U.S. launch of MagnetOs MIS Delivery System 8) New U.S. manufacturing facility underway (Atlanta area) 9) Expanded clinical evidence portfolio 10) International approvals secured (Brazil, Saudi Arabia, Lebanon) 11) EU MDR certification achieved 12) Multiple large U.S. IDN approvals secured Kuros has entered a new phase of operational scale and sustained profitability – driven by innovation, expanding global adoption of MagnetOs, and disciplined execution. Read the full press release here: https://hubs.ly/Q0469gkK0 #KurosBiosciences #MagnetOs #BoneHealing #Spine #Extremities #SIXSwissExchange

𝗞𝘂𝗿𝗼𝘀 𝗕𝗶𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝘁𝗼 𝗽𝗿𝗼𝘃𝗶𝗱𝗲 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿 𝘂𝗽𝗱𝗮𝘁𝗲 𝗮𝘁 𝘁𝗵𝗲 𝟮𝟬𝟮𝟲 𝗢𝗰𝘁𝗮𝘃𝗶𝗮𝗻 𝗮𝗻𝗱 𝗕𝗮𝗮𝗱𝗲𝗿 𝗕𝗮𝗻𝗸 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲𝘀 Today, Kuros announced a series of milestones that will be presented including: - Key IDN (Integrated Delivery Network) health system approvals - MDR certification achievement - Newly published head-to-head preclinical MagnetOsᵀᴹ evidence “Together, these achievements reinforce our position as an evidence driven biologics company and support the continued global adoption of MagnetOs as we execute on our long-term growth objectives.” - Chris Fair, CEO of Kuros To read more, click here for the full press release: https://lnkd.in/esEvpBVa #KurosBiosciences #MagnetOs #GrowBoneMagnetOs #NeedleGrip

𝗞𝘂𝗿𝗼𝘀 𝗕𝗶𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝘀 𝗲𝗻𝗿𝗼𝗹𝗹𝗺𝗲𝗻𝘁 𝗼𝗳 𝗳𝗶𝗿𝘀𝘁 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗶𝗻 𝗴𝗹𝗼𝗯𝗮𝗹 𝗔𝗦𝗧𝗥𝗔 𝘀𝘁𝘂𝗱𝘆 Kuros Biosciences today announced that the first patient has been enrolled in its global 𝗔𝗦𝗧𝗥𝗔 (𝗔𝗻𝗸𝗹𝗲 𝗦𝘂𝗯𝘁𝗮𝗹𝗮𝗿 𝗮𝗿𝗧𝗵𝗿𝗼𝗱𝗲𝘀𝗶𝘀 𝗥𝗮𝗻𝗱𝗼𝗺𝗶𝘇𝗲𝗱 𝗔𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁) clinical study. ASTRA is a prospective, randomized, controlled, multi-centered Level I trial evaluating MagnetOsᵀᴹ standalone (not mixed with other bone grafting materials) versus autograft in hindfoot and ankle fusion procedures across sites in the U.S., Australia, New Zealand, Europe and/or the Middle East. “We’re excited to participate and get the enrollment underway in this important global study,” said Dr. Jesse Doty, Orthopedic Surgeon and Principal Investigator at Erlanger Orthopaedics. “Successful bone fusion in complex hindfoot and ankle procedures can be challenging, especially when autograft availability or quality is limited.” This milestone marks an important step in expanding Kuros’ growing body of clinical evidence into new anatomical applications. To read the full press release, click here: https://lnkd.in/ese9F4cK #KurosBiosciences #ASTRAstudy #MagnetOs #Level1Data #GrowBoneMagnetOs #NeedleGrip